Currentcare_continuumPolicy n05621

Drug, Drug Metabolite and Alcohol Testing Frequency Policy

Customize your policy alerts

Sign up for care_continuum Policy n05621 alerts

Get alerted when Policy n05621 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity criteria, frequency limits, and non-covered indications for drug, metabolite and alcohol testing in behavioral health and chronic opioid therapy settings for Network Health members; applies to utilization management decisions by the payer's reviewers and treating practitioners.

Policy Summary

Payercare_continuum

PolicyDrug, Drug Metabolite and Alcohol Testing Frequency Policy

Policy CodePolicy n05621

Change TypeNo material change

Effective DateAug 21, 2025

Last ReviewAug 21, 2025

Next Review DateAug 21, 2026

Key ActionObtain and include a signed requesting practitioner order that specifies the exact test(s) for confirmatory and full-panel testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

coveredadmission/baseline

yearly minperiodic frequency

hair testingnot covered

conditionalconfirmatory

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentcare_continuumPolicy n05621

Drug, Drug Metabolite and Alcohol Testing Frequency Policy

Customize your policy alerts

Sign up for care_continuum Policy n05621 alerts

Get alerted when Policy n05621 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payercare_continuum

PolicyDrug, Drug Metabolite and Alcohol Testing Frequency Policy

Policy CodePolicy n05621

Change TypeNo material change

Effective DateAug 21, 2025

Last ReviewAug 21, 2025

Next Review DateAug 21, 2026

Key ActionObtain and include a signed requesting practitioner order that specifies the exact test(s) for confirmatory and full-panel testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

coveredadmission/baseline

yearly minperiodic frequency

hair testingnot covered

conditionalconfirmatory

Coverage Criteria and Indications

Covered Indications

Covered when ANY of the following are met:

Covered indications: 1) Drug screening/testing on admission to inpatient, residential, or intensive outpatient treatment (IP/Residential/IOP) for initial assessment or baseline; OR 2) Drug screening/testing prior to initiating chronic opioid therapy for initial assessment or baseline; OR 3) Additional drug screening/testing when the requesting practitioner will utilize results for treatment planning and any of: patient reports relapse; external reports of relapse; altered mental or physical status; other definitive information suggesting relapse; annual testing for chronic opioid therapy or more frequently with evidence of increased misuse risk; OR 4) Other medically necessary situations not outlined above.

From Procedure Detail II.A–C and II.F.2-6

Confirmatory Testing Criteria

Confirmatory testing is covered when ALL of the following are met:

Confirmatory testing criteria: a) The result of the drug test is different than that suggested by the patient’s medical history, clinical presentation, or patient's own report; AND b) There are inconsistent findings if previous tests were performed; AND c) The ordered confirmatory tests are not part of a predesignated laboratory panel; AND d) A signed requesting practitioner order deeming the laboratory test(s) medically necessary includes the specific name of the lab test(s) to be performed.

Procedure Detail II.D.1 a-d

Full Panel Screening Criteria

Full panel screening should be considered only when ALL of the following are met:

Full panel criteria: 1) The patient's observed behavior suggests use of drugs not identified on initial screening; AND 2) Medical documentation supports the behavioral observation and medical justification for conducting a full panel screening; AND 3) A signed requesting practitioner order deeming the laboratory test(s) medically necessary includes the specific name of the lab test(s) to be performed.

Procedure Detail II.E.1-3

Network Health does not cover routine or random drug screening or testing during inpatient, residential, or intensive outpatient (IP/Residential/IOP) treatment when there is no evidence suggestive of relapse. Testing ordered solely by third parties (for example, employers, schools, or courts) is not covered when there is no evidence suggestive of relapse. Additionally, when a urine drug screen (dipstick or simple screen) is consistent with the member’s prescribed medications and the member is not exhibiting unusual behaviors, further full-panel or confirmatory testing is not medically necessary.

Network Health considers drug testing via hair analysis NOT medically necessary and therefore does not cover hair-based drug testing under this policy.

When Testing Is Covered

Initial/baseline testing on admission to treatment or prior to initiating chronic opioid therapy; additional testing when used for treatment planning as specified.

Initial or baseline testing covered when the following indication is present:

Initial/baseline testing: Initial/baseline drug testing is covered when performed on admission to treatment (inpatient, residential, or intensive outpatient) or prior to initiating chronic opioid therapy; additional testing is covered when the requesting practitioner will use results for treatment planning as specified (e.g., reported relapse, external reports of relapse, altered mental/physical status, other definitive information suggesting relapse, or yearly/more frequent testing for chronic opioid therapy based on risk).

Procedure Detail II.A–C and II.F.2-6

Testing Frequency

inv-17: periodic urine drug testing (including chromatography)

Frequency for low-risk chronic opioid therapyPeriodic urine drug testing (including chromatography): at least yearly for low-risk patients

Increased-risk patientsTesting more frequently than yearly when there is evidence of increased risk of misuse (e.g., PDMP findings, violations of opioid agreement, altered mental/physical status, external reports of relapse)

Triggers for additional testingAdditional testing is covered if external agencies report relapse, patient reports relapse, mental/physical status appears altered, or other definitive information suggests relapse

Ongoing assessment componentsOngoing urine drug screening assessment includes review of PDMP, periodic pill counts for high-risk patients, and monitoring for opioid agreement violations

inv-07: Periodic urine drug testing frequency

Billing and Codes

CPT/HCPCS Codes referencedCPT | HCPCS

80305	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures (e.g., immunoassay); capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges); includes sample validation when performed, per date of service.
80306	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures (e.g., immunoassay); read by instrument assisted direct optical observation (e.g., dipsticks, cups, cards, cartridges); includes sample validation when performed, per date of service.
80307	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (e.g., utilizing immunoassay [e.g., EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (e.g., GC, HPLC), and mass spectrometry either with or without chromatography (e.g., DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF); includes sample validation when performed, per date of service.
G0480	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers; includes stable isotope or other universally recognized internal standards in all samples, method or drug-specific calibration and matrix-matched quality control material; qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed.
G0482	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers; includes stable isotope or other universally recognized internal standards in all samples, method or drug-specific calibration and matrix-matched quality control material; qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed.
G0659	Drug test(s), definitive, performed without method or drug-specific calibration, without matrix-matched quality control material, or without stable isotope/internal standard(s); qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes.

Ordering, Documentation, and Denial Triggers

Prior Authorization

Signed order required for confirmatory and full‑panel tests

Confirmatory and full-panel definitive tests require a signed requesting practitioner order that deems the test(s) medically necessary and specifies the exact name of the lab test(s) to be performed; confirmatory testing is appropriate only when the policy's confirmatory criteria are met (see confirmatory testing criteria).

Signed requesting practitioner order must include the specific name of the lab test(s) to be performed.
Confirmatory testing is only appropriate when a screening reveals non‑prescribed or illicit drug(s) and all confirmatory criteria (a–d) are met.

Documentation Required

Order must specify test name and medical necessity

A signed requesting practitioner order deeming the laboratory test(s) medically necessary must include the specific name of the lab test(s) to be performed for confirmatory testing or a full panel screening; this order is required on pre‑determination.

Non-Covered Services and Limitations

The following are not covered: hair analysis testing; routine or random drug screening/testing during IP/Residential/IOP without evidence suggestive of relapse; drug screening/testing ordered by third parties (employer, school, court) without evidence suggestive of relapse; testing to perform both blood and urine for the same drug simultaneously; and full-panel or confirmatory testing when an initial urine screen is consistent with prescribed medications and the member shows no unusual behaviors.

Hair testing is explicitly identified as not medically necessary and is excluded from coverage under this policy.

Definitions and Test Types

inv-13: Full Panel Screen

DefinitionFull Panel Screen: a drug test that screens for the most misused illicit and/or prescription drug classes.

Use caseConsidered only when observed behavior suggests drug use not identified on initial screening and medical documentation supports testing

Order requirementRequires a signed requesting practitioner order specifying the specific lab test(s) to be performed for medical necessity

inv-14: Qualitative (presumptive) drug testing

DefinitionQualitative (presumptive) drug testing: detects the presence or absence of a substance belonging to a general class of drugs; results expressed non‑numerically (positive/negative).

PurposeUsed as an initial screen to identify classes of substances present before confirmatory testing is considered

Background and Rationale

Drug testing (blood, urine, saliva, sweat, hair, breath) detects drugs and metabolites and supports treatment planning; detection windows vary and prolonged or frequent use can lengthen detectability. Clinical use of testing should be limited to the minimum frequency necessary to detect use and aligned with the member’s clinical history and presentation. Specifically, routine or random testing without evidence of relapse and hair analysis testing are not covered per policy; confirmatory and full-panel tests require a signed practitioner order and other clinical justification when used for treatment planning or to resolve inconsistent or unexpected results.